22/04/2019 20:00:00

FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

NEW YORK, April 22, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Akorn, Inc. (NASDAQ: AKRX)

Class Period: August 1, 2018 - January 8, 2019

Deadline: April 22, 2019

For more info:www.bgandg.com/akrx

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) Akorn’s management misled investors concerning the severity of Akorn’s manufacturing violations at its Decatur, Illinois facility; (2) Akorn’s responses to the Food and Drug Administration’s (“FDA”) Form 483—which contained a list of observations made by the FDA during its inspection of Akorn’s Decatur, Illinois facility in April and May 2018—would be deemed inadequate by the FDA; (3) Akorn repeatedly failed to correct manufacturing violations at this facility; (4) the foregoing would subject Akorn to heightened regulatory scrutiny by the FDA; and (5) as a result, Akorn’s public statements were materially false and misleading at all relevant times.

Health Insurance Innovations, Inc. (NASDAQ: HIIQ)

Class Period: February 28, 2018 - November 27, 2018

Deadline: April 22, 2019

For more info:www.bgandg.com/hiiq

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) a substantial portion of Health Insurance Innovations’ revenue was derived from third parties; (2) these third parties used deceptive tactics to sell Health Insurance Innovations’ policies, including overstating the policy’s coverage and/or selling under the licenses of employees who had no involvement in the underlying sales; (3) regulatory scrutiny of these third parties would materially impact Health Insurance Innovations’ operations; and (4) as a result of the foregoing, defendants’ positive statements about Health Insurance Innovations’ business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Amarin Corporation (NASDAQ:

AMRN

)

Class Period: September 24, 2018 - November 8, 2018

Deadline: April 23, 2019

For more info:www.bgandg.com/amrn

The Complaint alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

BGG Logo.jpg

Related content
18 Jun - 
Amarin to Present at the 2019 BMO Prescription For Succ..
07 Jun - 
CORRECTING and REPLACING -- Amarin to Present Findings ..
07 Jun - 
Amarin to Present Findings Regarding Challenges of Curr..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
ROHM's New Power Supply Monitoring IC with Built-In Self-Diagnostic Function that Supports Functional Safety
2
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sprint Corporation, Boston Scientific Corporation, Box, Inc. and Cloudera, Inc. and Encourages Investors to Contact the Firm
3
Equity Trustees appointed Authorised Corporate Director to the AllianceBernstein UK OEIC
4
Genocea Announces Pricing of $36,750,000 Public Offering of Common Stock
5
Atreca Announces Pricing of Initial Public Offering

Related stock quotes

Amarin Corporation plc -.. 19.40 -0.1% Stock price decreasing
Akorn Inc 4.740 1.9% Stock price increasing
Health Insurance Innovat.. 26.58 3.5% Stock price increasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 June 2019 01:16:25
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB3 - 2019-06-21 02:16:25 - 2019-06-21 01:16:25 - 1000 - Website: OKAY